{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Imlunestrant Improves Progression-Free Survival in Some Patients With Advanced Breast Cancer

Activity Steps

1 Activity
2 Take Test 3Certificate

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Summarize study results regarding the effect of imlunestrant on progression-free survival (PFS) in patients with advanced breast cancer.
  2. Evaluate the safety of imlunestrant for use with this patient population.

Learning Outcomes

By the conclusion of this activity, a majority of the participants will demonstrate knowledge of a study evaluating the role of the next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader imlunestrant, as monotherapy or in combination with the CDK4/6 inhibitor abemaciclib, in patients with ER-positive, HER2-negative advanced breast cancer by achieving a passing score on the posttest.

Disclosures

All authors and planners have no relevant financial relationships with any ineligible organizations regarding this educational activity.

Price: $12.95

Credits:

  • ANCC 1.0 CH
  • DC - BON 1.0 CH
  • FL - BON 1.0 CH
  • GA - BON 1.0 CH
  • NM - BON 1.0 CH
  • SC - BON 1.0 CH
  • WV - BOERN 1.0 CH

Lippincott Professional Development is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, Georgia Board of Nursing, New Mexico Board of Nursing, South Carolina Board of Nursing, and West Virginia Board of Examiners for Registered Professional Nurses, #50-1223.













Planner
Test Code: OT0325
Published: March 2025
Expires: 3/5/2027
Sources: Oncology Times
Required Passing Score: 4/5 (80%)
Authors: Catlin Nalley
Categories: Cancer , Drug Therapy , Oncology , Women's Health
Specialties: Oncology, Women's Health
Topics: Breast Cancer , Breast Diseases , Cancer , Chemotherapy